Patents by Inventor William Salomon

William Salomon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS
    Publication number: 20190161757
    Abstract: The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing. The RNAi constructs may be, for instance, miRNA constructs that are miRNA modulators.
    Type: Application
    Filed: June 28, 2018
    Publication date: May 30, 2019
    Applicant: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • Reduced size self-delivering RNAi compounds
    Patent number: 10240149
    Abstract: The present invention relates to methods for in vivo administration of sd-rxRNA molecules.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: March 26, 2019
    Assignee: Phio Pharmaceuticals Corp.
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • RNA interference in ocular indications
    Patent number: 10184124
    Abstract: The present invention relates to ocular administration of sd-rxRNA and rxRNAori molecules.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: January 22, 2019
    Assignee: Phio Pharmaceuticals Corp.
    Inventors: Lyn Libertine, Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia, Pamela A. Pavco
  • RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
    Publication number: 20180371464
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal and fibrotic applications.
    Type: Application
    Filed: March 12, 2018
    Publication date: December 27, 2018
    Applicant: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, Lyn Libertine, James Cardia, Karen G. Bulock
  • Neutral nanotransporters
    Patent number: 10138485
    Abstract: Neutral lipid formulations for nucleic acid delivery are provided according to the invention. The neutral lipid formulations include hydrophobically modified polynucleotides and fat mixtures. Methods of using the neutral lipid formulations are also provided.
    Type: Grant
    Filed: September 22, 2009
    Date of Patent: November 27, 2018
    Assignee: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Michelle Miller, Karen G. Bulock
  • Modified RNAi polynucleotides and uses thereof
    Patent number: 10131904
    Abstract: The invention relates to improved RNAi constructs and uses thereof. The construct has a double stranded region of 19-49 nucleotides, preferably 25, 26, or 27 nucleotides, and preferably blunt-ended. The construct has selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity. For example, the sense strand may be modified (e.g., one or both ends of the sense strand is/are modified by four 2?-O-methyl groups), such that the construct is not cleaved by Dicer or other RNAse III, and the entire length of the antisense strand is loaded into RISC. In addition, the antisense strand may also be modified by 2?-O-methyl group at the 2nd 5?-end nucleotide to greatly reduce off-target silencing. The constructs of the invention largely avoids the interferon response and sequence-independent apoptosis in mammalian cells, exhibits better serum stability, and enhanced target specificity.
    Type: Grant
    Filed: February 11, 2009
    Date of Patent: November 20, 2018
    Assignee: RXi Pharmaceuticals Corporation
    Inventors: Pamela A. Pavco, Joanne Kamens, Tod M. Woolf, William Salomon, Anastasia Khvorova
  • RNA INTERFERENCE IN SKIN INDICATIONS
    Publication number: 20180327748
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.
    Type: Application
    Filed: February 26, 2018
    Publication date: November 15, 2018
    Applicant: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, James Cardia
  • Reduced size self-delivering RNAi compounds
    Patent number: 10041073
    Abstract: The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing. The RNAi constructs may be, for instance, miRNA constructs that are miRNA modulators.
    Type: Grant
    Filed: March 23, 2011
    Date of Patent: August 7, 2018
    Assignee: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • RNA DUPLEXES WITH SINGLE STRANDED PHOSPHOROTHIOATE NUCLEOTIDE REGIONS FOR ADDITIONAL FUNCTIONALITY
    Publication number: 20180155718
    Abstract: The present invention relates to RNAi constructs and their use in gene silencing. RNAi constructs associated with the invention contain a double stranded region connected to a single stranded region of phosphorothioate modified nucleotides.
    Type: Application
    Filed: June 30, 2017
    Publication date: June 7, 2018
    Applicant: RXi Pharmaceuticals Corporation
    Inventors: Tod M. Woolf, Joanne Kamens, William Salomon, Anastasia Khvorova
  • RNA interference in dermal and fibrotic indications
    Patent number: 9963702
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal and fibrotic applications.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: May 8, 2018
    Assignee: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, Lyn Libertine, James Cardia, Karen G. Bulock
  • RNA interference in skin indications
    Patent number: 9938530
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.
    Type: Grant
    Filed: February 11, 2016
    Date of Patent: April 10, 2018
    Assignee: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, James Cardia
  • RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
    Patent number: 9745574
    Abstract: The present invention relates to RNAi constructs and their use in gene silencing. RNAi constructs associated with the invention contain a double stranded region connected to a single stranded region of phosphorothioate modified nucleotides.
    Type: Grant
    Filed: February 4, 2010
    Date of Patent: August 29, 2017
    Assignee: RXi Pharmaceuticals Corporation
    Inventors: Tod M. Woolf, Joanne Kamens, William Salomon, Anastasia Khvorova
  • RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
    Publication number: 20170067056
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal and fibrotic applications.
    Type: Application
    Filed: April 14, 2016
    Publication date: March 9, 2017
    Applicant: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, Lyn Libertine, James Cardia, Karen G. Bulock
  • RNA INTERFERENCE IN SKIN INDICATIONS
    Publication number: 20170009239
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.
    Type: Application
    Filed: February 11, 2016
    Publication date: January 12, 2017
    Applicant: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, James Cardia
  • REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS
    Publication number: 20160244765
    Abstract: The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing.
    Type: Application
    Filed: September 25, 2015
    Publication date: August 25, 2016
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • RNA interference in dermal and fibrotic indications
    Patent number: 9340786
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal and fibrotic applications.
    Type: Grant
    Filed: March 24, 2011
    Date of Patent: May 17, 2016
    Assignee: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, Lyn Libertine, James Cardia, Karen G. Bulock
  • REDUCED SIZE SELF-DELIVERING RNAI COMPOUNDS
    Publication number: 20160130578
    Abstract: The present invention relates to methods for in vivo administration of sd-rxRNA molecules.
    Type: Application
    Filed: June 2, 2015
    Publication date: May 12, 2016
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • RNA INTERFERENCE IN OCULAR INDICATIONS
    Publication number: 20160115482
    Abstract: The present invention relates to ocular administration of sd-rxRNA and rxRNAori molecules.
    Type: Application
    Filed: June 2, 2015
    Publication date: April 28, 2016
    Inventors: Lyn Libertine, Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia, Pamela A. Pavco
  • INHIBITION OF MAP4K4 THROUGH RNAI
    Publication number: 20160115484
    Abstract: RNAi constructs directed to MAP4K4 that demonstrate unexpectedly high gene silencing activities, and uses thereof are disclosed. The blunt-ended constructs have a double-stranded region of 19-49 nucleotides. The constructs have selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity. For example, the strands may be modified (e.g., one or both ends of the sense strand is modified by 2?-O-methyl groups), such that the construct is not cleaved by Dicer or other RNAse III, the antisense strand may also be modified by a 2?-O-methyl group at the penultimate 5?-end nucleotide to greatly reduce off-target silencing.
    Type: Application
    Filed: June 2, 2015
    Publication date: April 28, 2016
    Inventors: Tod M. Woolf, Joanne Kamens, Anastasia Khvorova, William Salomon
  • RNA interference in skin indications
    Patent number: 9303259
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: April 5, 2016
    Assignee: RXi Pharmaceuticals Corporation
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, James Cardia